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Introduction
Large granular lymphocytic (LGL) leukemia is a chronic lymphoproliferative disorder characterized by the expansion of CD3+CD8+CD57+ cytotoxic T-cells or CD3 neg CD16/56+ NK-cells. [1] [2] [3] It is often associated with severe cytopenias and other comorbidities such as rheumatoid arthritis; all thought to be autoimmune-based and mediated by cytotoxic LGL lymphocytes. 4 Leukemic
LGLs are resistant to Fas-mediated apoptosis, and both IL-15 and PDGFR have been shown to promote their survival. 5 In a previous study, we showed that 40% of T-LGL leukemia patients harbored a somatic STAT3 mutation in the Src-like homologue (SH2) domain of STAT3. 6 The amino acid changes increased the phosphorylation and transcriptional activity of STAT3, suggesting that in 40% of cases mutated STAT3 gene causes aberrant STAT3 signaling seen in LGL leukemia. A similar spectrum of STAT3 mutations and prevalence of 30% were also verified in NK-LGL leukemia. 7 However, it should be noted, that the expression of many STAT3
target genes was also increased in STAT3 mutation negative LGL leukemia cases, suggesting that in these patients other mechanisms resulting in the activation of the JAK-STAT pathway may operate. 6 To understand the molecular pathogenesis of LGL leukemia and discover the genetic basis of disease development in patients without a STAT3 mutation, we performed whole exome and transcriptome sequencing of two T-LGL leukemia patients lacking a STAT3 mutation, and validated the results in a large cohort of T-and NK-LGL leukemia patients.
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Methods

Study patients
The study was undertaken in compliance with the principles of the Helsinki declaration and was approved by the ethics committees in the Helsinki University Central Hospital (Helsinki, Finland), the Cleveland Clinic (Cleveland, Ohio) and the Penn State Hershey Cancer Institute (Hershey, Pennsylvania). All patients and healthy controls gave written informed consents.
The study population consisted of 211 patients with LGL leukemia: 173 patients had T-LGL and 38 patients NK-LGL leukemia. 101 samples were from the Penn State Hershey Cancer Institute, 87 from the Cleveland Clinic and 23 from Finland. All patients met the criteria of
LGL leukemia as defined by the WHO (2008) . The main characteristics of the patients are summarized in Supplementary Table 1 .
Sample collection and DNA/RNA extraction
Mononuclear cells (MNCs) were separated from peripheral blood (PB) using Ficoll gradient separation (GE Healthcare) and CD4+ and CD8+ T cells were further separated with magnetic beads separation: PB MNCs were labeled either with CD4 or CD8 MicroBeads (Miltenyi Biotech, San Diego, CA) according to instructions by the manufacturer and separated with an AutoMACS cell sorter (Miltenyi Biotech). The purity of the sorted fractions was confirmed by flow cytometry (FACSAria, Becton Dickinson). In NK-LGL cases, whole blood or the MNC fraction was used for analysis.
Genomic DNA was isolated from fresh or frozen sorted MNCs or from whole blood samples using the Genomic DNA NucleoSpin® Tissue kit (Macherey-Nagel). RNA was extracted using miRNAeasy kit (Qiagen). DNA and RNA concentration and purity were measured with the Nanodrop (Thermo Fisher), Qubit 2.0 Fluorometer (Life Technologies) and Agilent 2100 Bioanalyzer (Agilent Technologies).
TCR Vβ analysis
TCR Vβ families were analyzed from T-LGL leukemia patients' whole blood or PB MNC samples by combining CD4 and CD8 antibodies with the panel of TCR Vβ antibodies corresponding to 24 members of variable regions of the TCR β chain (about 70% coverage of normal human TCR Vβ repertoire) (Beckman-Coulter Immunotech). Samples were analyzed using FACSAria and FACSDiva Software (Becton Dickinson).
Exome sequencing
Exome sequence library preparation, Agilent exome capture and the bioinformatics pipeline for identification and annotation of candidate somatic mutations were performed as previously described. 6 
Microarray analysis
We used the Illumina Human HT-12 v4 BeadChip expression array (lllumina, San Diego, CA) which targets >47000 probes in the human genome (cover content from NCBU RefSeq Release 38 and legacy UniGene content). The data was read with an iScan instrument (Illumina) and primary analysis was done with Genome Studio software v2011.1 (Illumina).
Further normalization and analysis was performed with the Chipster open source platform. 8 Microarray data are available in the ArrayExpress database (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-1611.
Validation and screening of candidate somatic mutations by capillary sequencing
The candidate somatic mutations were validated with capillary sequencing and specific primers were designed using the Primer-Blast search (http://blast.ncbi.nlm.nih.gov/, National Center for Biotechnology Information, Bethesda, MD, USA). Capillary PCR products were either separated by gel electrophoresis and extracted from the gel using the QIAquick Gel Extraction Kit (QIAGEN) or purified using the ExoSAP-IT for PCR Product Clean-Up kit (Affymetrix). The purified PCR products were then sequenced with BigDye™ v.1.1 Cycle Sequencing kit and the ABI PRISM® 3730xl DNA Analyzer. Sequences were analyzed using Chromas Pro and Blast search. The primer sequences are in Supplementary Table 2 .
Amplicon sequencing of STAT5b
Locus specific primers were designed to cover STAT5a exon 17 and STAT5b exon 16 using Primer3 with user-defined parameters (http://primer3.wi.mit.edu/). Primers were designed for maximum 300-nucleotide-long PCR amplicons. The locations of SNPs were masked using dbSNP-build 135. Repeat masking was not performed. After designing the locusspecific primer sequences, sequence tails corresponding to the Illumina adapter sequences, 5'-ACACTCTTTCCCTACACGACGCTCTTCCGATCT and 5'-AGACGTGTGCTCTTCCGATCT, were added to the 5'-end of the forward and reverse Table 4 
STAT5b mutagenesis
An expression plasmid pCMV6-XL6 containing the wild type coding sequence of STAT5b (OriGene, SC115355) was modified to include the Y665F and N642H mutations. The mutant constructs were created using the GENEART® Site-Directed Mutagenesis System (Invitrogen) according to the manufacturer's protocol. The primer sequences used for the mutagenesis are in Supplementary 
Western blot analysis
Transiently transfected HeLa cells were lysed in SDT lysis buffer 6 and approximately 6 µg 
Subcellular fractionation of patient samples
Subcellular fractionation and western blotting have been performed as described previously. 6 The different fractions of normalized protein aliquots were separated on either an 8% or 15% SDS-PAGE gel and next transferred to a PVDF membrane. The membranes were incubated with the following primary antibodies; rabbit anti-phospho ( 
STAT5b protein structure analysis
A homology model of the human STAT5b monomer (Uniprot sequence ID P51692) was retrieved from the SWISS-MODEL repository. 9 The STAT5b dimer structure was modeled by aligning the STAT5b monomer to two monomers in the mouse STAT3 dimer crystal structure template (RCDB ID: 1bg1) 10 and structural coordinates of the bound DNA fragment where copied from 1bg1. Structural alignments were generated by Dali pairwise comparison.
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Microarray data analysis
Microarray data was normalized and log2-transformed with Chipster as described previously. 12, 13 Similarity of expression profiles was determined using pairwise Pearson correlation and a distance dendrogram was constructed using the average linkage method.
Differentially expressed genes were detected using the empirical Bayes test with p-value cut-off of 0.05. 14 KEGG pathway-analysis for over-expressed genes was performed with a hypergeometric test.
Results
STAT5b mutation identified by exome sequencing
Two patients with untreated T-LGL leukemia and no STAT3 mutation were chosen for exome sequencing (patients 1 and 2, Table 1 The other genes, which harbored validated somatic mutations in addition to STAT5b, included bone morphogenetic protein receptor type II (BMPR2) in patient 1, and sphingomyelin synthase 2 (SGMS2) and early B-cell factor 3 (EBF3) in patient 2 ( Table 2) .
Screening of STAT5b and STAT5a mutations in LGL leukemia patient cohort
We designed deep next-generation sequencing primers for STAT5b exon 16 containing the Y665F mutation, and standard capillary sequencing primers for adjacent exons 14-15 and 17-18. The screening cohort consisted of 171 LGL leukemia patients with T-cell phenotype and 38 patients with NK phenotype (Supplementary Table 1 ). Two additional
LGL leukemia patients (patients 3 and 4 in Table 1 ) were found to have a different somatic missense mutation N642H in the STAT5b SH2 domain (Figures 2A-b; Figure 3 ; Table 3 ), while no STAT5b mutations were detected in the rest of the patients. Patient number 3 had a CD3+ T-cell phenotype, but the LGL cells also expressed CD56 antigen ( Figure 3A ). The population-variation data sets were also screened, but the identified mutations were not present in either database.
The BMPR2, SGMS2 and EBF3 mutations found by exome sequencing in two patients with STAT5b mutations were also screened by capillary sequencing from 77 LGL-leukemia patients, but none harbored these mutations.
STAT5 is phosphorylated and translocated into the nucleus
One of the crucial steps in STAT5b activation is phosphorylation by tyrosine kinases, dimerization by trans-phosphotyrosine binding and translocation of the dimers to the nucleus. 16 The localization of total and phosphorylated STAT5 was analyzed by western blotting of lysed mononuclear cells and cytosolic and nuclear lysates. Samples were available from both patients with STAT5b mutation Y665F and from a healthy control. Both
STAT5b mutated patients expressed pSTAT5b in the nuclear fraction, whereas no pSTAT5b was detected in cells derived from healthy control ( Figure 4A ). In addition, nuclear fractions were extracted from 3 LGL-leukemia patients without STAT5b mutations and from 5 healthy The western blot results were confirmed with pSTAT5 and total STAT5 ELISA and the results were congruent: the two patients (1 and 2) with STAT5b mutation Y665F expressed higher amount of pSTAT5 when compared to all other samples ( Figure 4B ).
Gene expression analysis of LGL leukemia patients based on STAT3/STAT5b mutation status
Gene expression analysis was performed using the HumanHT-12 v4 Expression BeadChip array. RNA was extracted from CD8+ cells from 2 patients with STAT5b mutation Y665F, 1 patient with STAT5b mutation N642H, 3 patients with STAT3 mutation, 2 LGL patients without mutation in STAT3/STAT5b and 2 healthy controls. In addition NKcells from 2 healthy controls were sorted and used in the analysis.
The clustering analysis based on the gene expression data showed that both patients with STAT5b Y665F mutation were grouped together and were further clustered with other LGL leukemia patients (both STAT3 mutation-positive and STAT3/STAT5b mutation-negative patients) ( Figure 4C ). However, patient 4 with STAT5b mutation N642H and aggressive NK-LGL leukemia diverged from all other patients.
The comparison of the gene expression profile between patients with STAT5b mutation Y665F and healthy controls showed that 4894 genes were differentially expressed (p<0.05).
56 genes with a fold change of either >2.5 or <-2.5 (log 10 -scale) are presented in Supplementary Table 7 . Many of the genes upregulated in patients with the STAT5b mutations were also upregulated in other LGL leukemia patients ( Figure 4D ) suggesting that related signaling pathways operate despite of the mutation status of LGL cells. Interestingly, the KEGG pathway analysis identified that in patients with STAT5b mutations, the chronic myeloid leukemia pathway is enriched (Supplementary Table 8 ), which supports well STAT5 activation. In addition, protein synthesis, cell cycle and metabolic pathways were over-represented (Supplementary Table 8 ).
Clinical characteristics of the patients with STAT5b mutations
Both patients with the STAT5b mutation Y665F had CD3+CD8+CD56+TCRαβ+ lymphocytosis in peripheral blood and bone marrow, and >90% of CD3+CD8+ T-cells Figure 3A; Supplementary Figure 2) . The patient died despite receiving systemic chemotherapy, and the autopsy indicated extensive lymphocyte infiltration in the bone marrow, stomach, small bowel, lungs, liver, spleen, and lymph nodes. The other patient with a STAT5b N642H mutation (patient 4) had NK-LGL leukemia with normal karyotype, and symptoms included neutropenia, hemolytic anemia and splenomegaly (Table 1; Figure 3G ).
The patient was treated by splenectomy, which induced hematological remission, but after 7 years of follow-up he developed chemorefractory LGL leukemia and eventually died due to his disease. The two patients with STAT5b N642H mutation were the only ones with aggressive LGL leukemia in our patient cohort.
Both mutants Y665F and N642H increase the transcriptional activity of STAT5b
For the analysis of the transcriptional activity of mutated STAT5b, the Y665F and N642H mutation constructs were transiently transfected to HeLa-cells simultaneously with a luciferase sequence under the control of a STAT5-binding element. The analysis was done with unstimulated cells, and both mutants clearly induced increased luciferase activity when compared to the wild-type STAT5b plasmid ( Figure 5A ). The cells with the N642H construct exhibited stronger activation of transcription.
After the luciferase experiment, transfected HeLa-cells were lysed and both the total STAT5 and pSTAT5 were measured by western blot analysis. The results were congruent with the luciferase assay: especially the N642H mutant showed increased phospho-STAT5 expression when compared to the wild-type STAT5 (Figure 5B-C) .
Discussion
To our knowledge, this is the first description of somatic STAT5 mutations in human cancer patients, although STAT5 plays an important role in many hematological malignancies and solid tumors. Exome sequencing followed by targeted Sanger and amplicon sequencing 24 Considering the immunological aspects of STAT5 genes, Stat5a deficiency in mice leads to decreased T-and NK-cell proliferation in response to antigenic stimulation. 25 Furthermore, both basal and IL-2 induced cytolytic activity of NK-cells is considerably diminished in STAT5b -/-mice, suggesting that STAT5b plays a major role in NK-cell activation. 25 There are also a few case reports of STAT5b deficient patients who have reduced numbers of NK-cells. 26 Interestingly, in our study, the leukemic T-LGL cells of all patients with STAT5B mutations expressed the CD56 NK-marker, and one patient had a NK-phenotype suggesting that activating STAT5b mutations might be associated with transformation of cells related to the NK-cell lineage.
The STAT5b mutations described in this paper were located in the SH2 domain, close to the phospho-tyrosine-binding loop (N642H) and transactivation domain (Y665F). 10 Based on the three-dimensional structure, we hypothesize that the mutations stabilize the dimer in chronic myeloid leukemia BCR/ABL expression leads to STAT5 activation, 27 and in myeloproliferative diseases STAT5 is activated by mutated JAK2. 28 In a network model of
LGL LGLs. 29 Similarly, in a mouse model prolonged IL-15 overexpression led to malignant transformation of LGL cells. 30 Furthermore, in a previous study, which first described activated STAT3 in LGL leukemia, 2 of 12 patients expressed also concurrently activated STAT5. 31 Our microarray data suggests that gene expression patterns in LGL leukemia patients with different mutation status resemble each other. This is in accordance with recent findings showing that in T-cells STAT3 and STAT5 share many downstream target genes. 32 According to published in vitro studies, mutations in STAT5 itself seem to be able to act as a primary event in malignant transformation. 33 The oncogenic potential of STAT5b mutation N642H, established now in two LGL leukemia patients, was demonstrated previously by Ariyoshi et al. as they showed that the transduction of the N642H mutant to mouse Ba/F3 cells led to the IL-3 independent growth of these cells causing constitutive phosphorylation and even prolonged hyperphosphorylation of STAT5 when Ba/F3 cells were stimulated with IL-3. 33 Despite these biologic properties, no mutations in STAT5a or STAT5b were observed in a cohort of 49 patients with acute leukemia. 34 Although the number of patients with STAT5 mutations is small and no definitive conclusions between mutations and clinical characteristics can be made, it is intriguing that the N642H mutation seems to be associated with more severe disease. Both patients with the N642H mutation had atypical, aggressive chemorefractory LGL leukemia and died due to their disease. This corresponds well with the in vitro findings showing that N642H is more active than the Y665F mutation. Specific STAT5 inhibitors have not entered in clinical trials yet, but it is tempting to speculate that they may have therapeutic potential in LGL patients with STAT5 mutations. However, already now there are some molecules, which inhibit the function of STAT5, such as the psychotropic drug pimozide, which was discovered in cellbased screens. 35 In a chronic myeloid leukemia model it was shown to induce apoptosis without inhibiting the BCR-ABL1 kinase. 35 In conclusion, this study identified somatic, activating mutations in the STAT5b gene, further emphasizing the role of STAT family genes in the pathogenesis of LGL leukemia. In particular, STAT5b N642H mutations were related to aggressive clinical disease and studies evaluating the therapeutic potential of STAT5 inhibitors are warranted. 
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